Hot Features
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatmen... XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.12 | -3.97350993377 | 3.02 | 3.02 | 2.82 | 80 | 2.89 | CS |
| 4 | -0.46 | -13.6904761905 | 3.36 | 3.54 | 2.75 | 408 | 3.11787465 | CS |
| 12 | 2.26 | 353.125 | 0.64 | 4.83 | 0.5 | 1864 | 3.25995321 | CS |
| 26 | 2.05 | 241.176470588 | 0.85 | 4.83 | 0.485 | 3336 | 1.38776762 | CS |
| 52 | 1.7 | 141.666666667 | 1.2 | 4.83 | 0.485 | 4653 | 1.28038871 | CS |
| 156 | 2.05 | 241.176470588 | 0.85 | 9.35 | 0.33 | 8710 | 2.07414305 | CS |
| 260 | -1.89 | -39.4572025052 | 4.79 | 9.35 | 0.33 | 10654 | 1.95916361 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.